Alexander D. Douglas

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Shuo Feng, Daniel J. Phillips, Thomas White et al. · Nature Medicine · 2021 · 1.2K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2021 · 1.2K citations · Full text

Veterinary Medicine, Immunology, Immunization +16

Correction: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

Alexander D. Douglas, Andrew R. Williams, Joseph J. Illingworth et al. · Nature Communications · 2013 · 926 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14